Sara K. Quinney, PhD
Professor of Obstetrics & Gynecology
Professor of Medicine
Adjunct Professor, Health Informatics, School of Informatics and Computing
Director, Indiana CTSI Pharmacometrics Modeling and Simulation Program
Director, IUSCCC Clinical Pharmacology Analytical Core
- squinney@iu.edu
- Address
-
950 W. Walnut St., R2 476
OBGY
Indianapolis, IN 46202 - PubMed:
-
Bio
Sara K. Quinney, Pharm.D., Ph.D., is a Professor in the Department of Obstetrics and Gynecology and Division of Clinical Pharmacology, Department of Medicine, at Indiana University School of Medicine where she serves as the Director of the Indiana Clinical and Translational Sciences Institute (CTSI) Pharmacometric Modeling and Simulation Program. She received her Pharm.D. and Ph.D. in pharmacy practice from Purdue University and completed clinical pharmacology and bioinformatics fellowships at Indiana University.
Dr. Quinney utilizes in vitro, preclinical, clinical, and bioinformatics data to develop quantitative systems pharmacology models to improve understanding of drug disposition and response in special populations, particularly in maternal and pediatric populations. She leads the Indiana University-Ohio State University Maternal and Pediatric PRecision in Therapeutics (MPRINT) Data and Model Knowledge Research Coordination Center (DMKRCC, P30HD106451), with a goal of enhancing maternal and pediatric pharmacotherapy through integrating data using innovative pharmacometric modeling approaches. Dr. Quinney also supports preclinical drug development efforts and serves as the clinical pharmacology and pharmacokinetic/ pharmacodynamic modeling expert for the IU Simon Comprehensive Cancer Center, Model Organism Development and Evaluation for Late-onset Alzheimer’s Disease (MODEL-AD, U54AG054345) and the IU/Purdue Target Enablement to Advance Therapeutics for Alzheimer’s Disease (TREAT-AD, U54AG065181) Preclinical Testing Cores. Dr. Quinney has served as a mentor to numerous students, residents, postdoctoral fellows, and junior faculty from a variety of disciplines.
Key Publications
Haas DM, Daggy J, Flannery KM, Dorr ML, Bonsack C, Bhamidipalli SS, Pierson RC, Lathrop A, Towns R, Ngo N, Head A, Morgan S and Quinney SK. A comparison of vaginal versus buccal misoprostol for cervical ripening in women for labor induction at term (the IMPROVE trial): a triple-masked randomized controlled trial. Am J Obstet Gynecol (2019) 221(3): 259.e251-259.e216. DOI: 10.1016/j.ajog.2019.04.037 PMID: 31075246
McDowell ML, Tonismae TR, Slaven JE, Abernathy MP, Shanks AL, Benjamin TD and Quinney SK. The Impact of Hepatitis C Virus Infection on Buprenorphine Dose in Pregnancy. Am J Perinatol (2019). DOI: 10.1055/s-0039-1698838 PMID: 31655490
Quinney SK. Opportunities and Challenges of Using Big Data to Detect Drug-Drug Interaction Risk. Clin Pharmacol Ther (2019) 106(1): 72-74. DOI: 10.1002/cpt.1481 PMC6617974. PMID: 31184772
Quinney SK, Gullapelli R and Haas DM. Translational Systems Pharmacology Studies in Pregnant Women. CPT Pharmacometrics Syst Pharmacol (2018) 7(2): 69-81. DOI: 10.1002/psp4.12269 PMC5824114. PMID: 29239132
Quinney SK, Benjamin T, Zheng X and Patil AS. Characterization of Maternal and Fetal CYP3A-Mediated Progesterone Metabolism. Fetal Pediatr Pathol (2017) 36(5): 400-411. DOI: 10.1080/15513815.2017.1354411 PMC5704987. PMID: 28949811
| Year | Degree | Institution |
|---|---|---|
| 2004 | PhD | Purdue University |
| 2000 | PharmD | Purdue University |
Pharmacokinetics and Pharmacodynamics of Drugs in Pregnancy
During pregnancy, a woman’s body undergoes many changes that can affect drug disposition (pharmacokinetics, PK) and effect (pharmacodynamics, PD). This can then help us determine optimal therapeutic regimens for pregnant women. Pharmacokinetic modeling, including physiologically based PK modeling, allows us to explore factors that may affect drug disposition, including changes in maternal metabolism and the addition of placental and fetal drug metabolism. Based on in vitro and clinical data, we are examining the pharmacokinetics of a variety of drugs during pregnancy.
Drug-Drug Interaction Research
Adverse drug reactions (ADRs) contribute to 100,000 deaths annually, making it the 5th leading cause of death. Drug-drug interactions (DDI’s) are a large contributor to ADRs. Working with Dr. Lang Li in the Center for Computational Biology, our lab integrates findings from electronic medical records with in vitro mechanistic experiments to help identify and understand the contribution of DDI’s to ADRs. Our studies focus primarily on pharmacokinetic DDI’s associated with inhibition and induction of Cytochrome P450 (CYP) enzymes. CYP enzymes are responsible for the majority of Phase 1 drug metabolism.
Pharmacometric Modeling
My research spans a large range of pharmacometric and big data applications, including physiologically based pharmacokinetic modeling, text mining, and machine learning approaches. I am involved in a number of collaborative research endeavors, including the MODEL-AD preclinical trial core, TREAT-AD, and projects in oncology.
Quinney SK; Benjamin T; Zheng X; Patil AS; Fetal and pediatric pathology 2017 Sep 26
Chiang CW; Zhang P; Wang X; Wang L; Zhang S; Ning X; Shen L; Quinney SK; Li L; Clinical pharmacology and therapeutics 2017 Oct 20
Zhang P; Wu HY; Chiang CW; Wang L; Binkheder S; Wang X; Zeng D; Quinney SK; Li L; CPT: pharmacometrics & systems pharmacology 2017 Nov 28
Wang X; Zhang P; Chiang CW; Wu H; Shen L; Ning X; Zeng D; Wang L; Quinney SK; Feng W; Li L; Statistics in medicine 2017 Nov 23
Towns R; Quinney SK; Pierson RC; Haas DM; AJP reports 2017 Jul 25
Quinney SK; Gullapelli R; Haas DM; CPT: pharmacometrics & systems pharmacology 2017 Dec 14
Nader AM; Quinney SK; Fadda HM; Foster DR; The AAPS journal 2016 Apr 22